Infliximab for the treatment of Crohn's disease: Review and indications for clinical use in Canada

Canadian Journal of Gastroenterology

Volumn 15, Issue 6, 2001, Pages 371-375

  Panaccione, R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ARTHRALGIA; ARTHRITIS; ARTICLE; BEHCET DISEASE; CANADA; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DAILY LIFE ACTIVITY; DELAYED HYPERSENSITIVITY; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DOSE RESPONSE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; ENTEROCUTANEOUS FISTULA; FEVER; FLUSHING; HEADACHE; HUMAN; INFECTION; LYMPHOMA; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; REMISSION; SCORING SYSTEM; SIDE EFFECT; SKIN MANIFESTATION; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; THORAX PAIN; ULCERATIVE COLITIS; URTICARIA; VOMITING; WEIGHT REDUCTION; WORK ENVIRONMENT;

EID: 0034916302     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/490921     Document Type: Article

References (26)

1. Antitumor necrosis factor therapy of inflammatory bowel disease: A review of agents, pharmacology, clinical result and safety
2. Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications
3. Tumor necrosis factor alpha antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
4. Development of a Crohn's disease activity index. National cooperative Crohn's disease study
5. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
6. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
7. Clinical experience with infliximab therapy in 100 patients with Crohn's disease
8. Infliximab in Crohn's disease: First anniversary clinical experience
9. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients
10. Infliximab for the treatment of fistulas in patients with Crohn's disease
11. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
12. Preliminary experience with infliximab in the treatment of refractory and fistulizing Crohn's disease (CD)
13. Efficacy and safety of infliximab treatment for refractory and fistulizing Crohn's disease in a Dutch expanded access program
14. Infliximab therapy for Crohn's disease fistulae: Number of infusions required for response and time to relapse
15. Clinical efficacy of treatment with infliximab in a German multicenter, prospective, open-label trial in refractory Crohn's disease
16. Review article: Safety of infliximab in clinical trials
17. Long-term follow-up of patients treated with infliximab (anti-TNFα antibody) in clinical trials
18. The relationship between infliximab treatment and lymphoma in Crohn's disease
19. The incidence of non-Hodgkin's lymphoma in hospitalized Crohn's disease patients in Virginia - An administrative database study
20. Chimeric monoclonal anti-tumour necrosis factor antibody (ca2) in the treatment of severe steroid refractory ulcerative colitis
21. Successful management of Crohn's disease of the ileonal pouch with infliximab
22. Twenty cases of peristomal pyoderma gangrenosum: Diagnostic implications and management
23. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: A case report
24. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease
25. Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms